Dyadic International, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark A. Emalfarb
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1044 North U.S. Highway One Jupiter FL United States of America 33477-5094
- IPO Date
- Jan 16, 2008
- CIK
- 0001213809
- Website
- dyadic.com
- Similar Companies
- Business
- Dyadic International, Inc. Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company that develops and commercializes proprietary microbial expression platforms, including the C1 and Dapibus expression systems based on the fungal host Thermothelomyces heterothallica, for the scalable production of high-value recombinant proteins and enzymes; these platforms enable the manufacture of animal-free input proteins for life sciences applications such as research reagents, diagnostics, therapeutics, bioprocess inputs including recombinant human albumin and transferrin, food and nutrition ingredients like non-animal dairy enzymes, and bio-industrial enzymes for biofuels, textiles, specialty chemicals, and cellulosic biomass conversion via products such as the EN3ZYME cocktail. Founded in 1979 and headquartered in Jupiter, Florida, the company originally focused on industrial enzymes and textiles before transitioning to biotechnology, serving customers across life sciences, food and nutrition, and bio-industrial markets worldwide with GRAS-designated, cGMP-capable production validated at scales exceeding 100,000 liters. In 2025, Dyadic Applied BioSolutions rebranded to emphasize applied biotechnology solutions, completed a strategic pivot from R&D to commercial revenue focus with first bulk protein sales, achieved multiple milestones including $1.5 million in payments from its Proliant Health & Biologicals partnership for recombinant human albumin targeting commercial launch in late 2025 or early 2026, advanced collaborations with Inzymes ApS and Fermbox Bio yielding purchase orders and 50/50 profit sharing on EN3ZYME, entered a non-exclusive CRISPR/Cas9 license with ERS Genomics to enhance genetic engineering capabilities, expanded into Japan and South Korea via partnership with Intralink, and conducted a public stock offering to fund product development and marketing.
Company News
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)
Dyadic International Targets Commercial Traction as Life Sciences Products Launch
Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review
Dyadic International (NASDAQ:DYAI) Stock Breaks Below 50-Day Moving Average – Here’s Why
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Dyadic International (NASDAQ:DYAI) Stock Passes Below 50-Day Moving Average – Time to Sell?
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Dyadic Announces Continued Listing on the Nasdaq Capital Market
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Dyadic Expands IP Protection and Business Development Activities in Japan
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development